ArticleMikrochimica acta2026
Comparative performance of biopolymer-supported graphitic carbon nitride nanosheets for electrochemical carcinoembryonic antigen cancer biomarker detection in serum samples using smartphone device.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoembryonic antigen (CEA) is a critical biomarker expressed in several cancers, necessitating the development of an ultrasensitive and selective detection platform for early-stage cancer diagnosis and monitoring treatment responses. Therefore, a comparative study related to electrochemical immunosensor for CEA detection between utilization of biopolymer functionalized graphitic carbon nitride nanosheets (f-gC₃N₄ NS) and pristine graphitic carbon nitride nanosheets (gC₃N₄ NS) onto screen printed electrode (SPE) is presented. The synthesis of gC₃N₄ NS was achieved via exfoliation process, followed by the functionalization of prepared gC₃N₄ NS using chitosan and their depostion onto SPE surface. Further, prepared f-gC₃N₄ NS/SPE surface was immobilized with specific activated antibodies for CEA (anti-CEA) using N-ethyl-N'-(3-dimethyl aminopropyl) carbodiimide (EDC) and N-hydroxy succinimide (NHS) coupling chemistry, ensuring sturdy and stable antibody attachment. In addition, bovine serum albumin (BSA) protein was used as a blocking agent to minimize non-specific interactions. The stepwise modified SPE platform was confirmed through morphological, structural and electrochemical techniques. The fabricated f-gC₃N₄ NS based immunoelectrode i.e. BSA/anti-CEA/f-gC₃N₄ NS/SPE was tested with various CEA concentrations ranging from 0.0001 to 20 ng/mL using differential pulse voltammetry (DPV) technique, showcasing a sensitivity of 4.71 µA/log(ng/mL)/cm². However, a comparison study was performed with pristine gC₃N₄ NS i.e.BSA/anti-CEA/gC₃N₄ NS/SPE, showed change in current response with the function of CEA concentrations ranging from 0.0001 to 5 ng/mL, exhibiting a sensitivity of 1.42 µA/log(ng/mL)/cm². The highly improved electrochemical performance of the BSA/anti-CEA/f-gC₃N₄ NS/SPE immunosensor was achieved due to the availibility of abundant functional groups present in f-gC₃N₄ NS providing strong biomolecular interactions with anti-CEA as well as improved surface area. Further, the obtained electrochemical immunosensing results with standard CEA biomarker were compared and validated with colorimetric immunoassay kit. The findings highlights the performance of the fabricated BSA/anti-CEA/f-gC₃N₄ NS/SPE in terms of selectivity, specificity, reproducibility and accuracy along with its capability to be used for onsite diagnosis of CEA biomarker in serum samples using smartphone assisted portable electrochemical device.
Indexed as
Identifiers
42406175What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.